Stephen Davis - Apr 5, 2024 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Jennifer J. Rhodes, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Apr 5, 2024
Transactions value $
-$474,877
Form type
4
Date filed
4/9/2024, 06:00 PM
Previous filing
Mar 27, 2024
Next filing
May 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +17.3K +14.58% 136K Apr 5, 2024 Direct F1
transaction ACAD Common Stock Options Exercise +34.7K +25.46% 171K Apr 5, 2024 Direct F1
transaction ACAD Common Stock Sale -$158K -8.86K -5.18% $17.87 162K Apr 8, 2024 Direct F2, F3
transaction ACAD Common Stock Sale -$317K -17.7K -10.94% $17.87 144K Apr 8, 2024 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -17.3K -33.33% $0.00 34.7K Apr 5, 2024 Common Stock 17.3K Direct F1, F5
transaction ACAD Restricted Stock Units Options Exercise $0 -34.7K -20% $0.00 139K Apr 5, 2024 Common Stock 34.7K Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.775 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.77 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The restricted stock units vest in four equal annual installments beginning April 5, 2023.
F6 Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from April 5, 2022 (the "grant date"); 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date.